Barcelona – January 2016 – Sagetis is pleased to announce that MINECO has granted funding to the BRAIN DELIVERY project (RTC-2015-3751-1) – New formulation technologies for improving the access of therapeutic oligonucleotides to the central nervous system (CNS).
The consortium led by nLife Therapeutics also involves research groups from IQS (GEMAT) and Fundación para la Investigación Biomédica del Hospital Universitario Ramon y Cajal. The consortium will receive 696K€ in funding from the Ministerio de Economía y Competitividad (MINECO), programa RETOS DE COLABORACIÓN, 2015.
The main goal of BRAINDELIVERY consortium is to implement a new technological approaches to facilitate access of macromolecules to the Central Nervous System (CNS), improving their bioavailability and pharmacokinetics.
About Sagetis Biotech
At Sagetis Biotech we are devoted to developing innovative drug delivery technologies to tackle challenging unmet medical needs. Based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.
The company's versatile, polymeric-based platforms are designed to tackle highly challenging areas, such as (i) delivery through difficult-to-cross barriers(e.g. blood-brain barrier, intestinal mucus gel layer, ocular); (ii) efficient transfection of genetic material, using both viral and non-viral vectors.
The Grup d’Enginyeria de Materials was founded in the year 1994 by Dr. Salvador Borrós, a current Full Professor in Material Science, with the objective of giving research service to the teaching community on this subject. From the beginning, the Group’s efforts were driven to the field of polymeric materials, specially elastomers, conductive polymers and surface treatment.
By this time, the main research fields have been established: conductive polymers, rubber, ceramic materials and surface modification. In 2003, the Group organizes in Barcelona the 1st Workshop in Bioengineering. In the year 2004, the 2nd Workshop takes place, now with the support of the IQS; the 3rd and 4th events were to follow. The IQS has been, through the Group, the founder of the European Technological Platform in Nanomedicine
About nLife Therapeutics
nLife Therapeutics is an early-stage biopharmaceutical company leading developments in nOligos (neuronal specific oligonucleotides) as therapeutic agents for CNS disorders. nLife has a unique oligonucleotide delivery platform with strong IP protection to target several neurodegenerative conditions.
Its lead candidate (NLF-PD-1233) is a First in Class disease modifying oligonucleotide treatment for Parkinson’s disease (PD). The company has outstanding preclinical data that validates the nOligos Mode of Action in Major Depressive Disorder and PD. The company also has programs targeting Huntington and Alzheimer disease underway.
About Fundación Biomédica Ramon y Cajal
La Fundación Biomédica del Hospital Universitario Ramon y Cajal was born with the objective of providing a practical application for scientific and technical research and to strengthen the areas of teaching in the field of health sciences at the Hospital Universitario Ramon y Cajal.
This hospital has a large scientific and research community, assigned to a Department of Research and distributed among the various clinical, surgical and Central Services. This has led to a remarkable scientific production, as evidenced in detail in the annual reports, available on the Web and on CD.
The Foundation was established, therefore, with the aim to promote and encourage research in its broadest sense and revert to the Company the application of scientific advances, through improved quality of care and patient care.